ariad, rochester

custom search

REVERSED
Tech Center 1600 Biotechnology and Organic Chemistry
1611 Ex Parte Liu et al 12598138 - (D) PAULRAJ 103/double patenting OBLON, MCCLELLAND, MAIER & NEUSTADT, LLP, ROBINSON, LISBETH C

Tech Center 1700 Chemical & Materials Engineering
1736 Ex Parte Scarsbrook et al 11743680 - (D) GUPTA 112(1)/112(2)/103 KILPATRICK TOWNSEND & STOCKTON LLP MCCRACKEN, DANIEL

Tech Center 2400 Networking, Multiplexing, Cable, and Security
2412 Ex Parte Pham et al 13026369 - (D) JURGOVAN 103 Blank Rome LLP Brocade KAMARA, MOHAMED A

2458 Ex Parte Fernandez Alonso et al 13461227 - (D) HAGY 103 ERICSSON INC RECEK, JASON D

Tech Center 2600 Communications
2664 Ex Parte Jiao et al 12645916 - (D) HAAPALA 103 HONEYWELL/HUSCH MOE, AUNG SOE

Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2876 Ex Parte Smith et al 13107560 - (D) DELMENDO 103 Faegre Baker Daniels LLP GOOGLE MIKELS, MATTHEW

2898 Ex Parte Flachowsky et al 13345922 - (D) OWENS 102/103 Amerson Law Firm, PLLC GLOBALFOUNDRIES INC. HOSSAIN, MOAZZAM

Tech Center 3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
3623 Ex Parte Chee et al 12201073 - (D) MEDLOCK 103 SCULLY, SCOTT, MURPHY & PRESSER, P,C SWARTZ, STEPHENS

3686 Ex Parte Demeester et al 12740358 - (D) HUTCHINGS 103 PHILIPS INTELLECTUAL PROPERTY & STANDARDS PATEL, NEHA

Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3721 Ex Parte Lancaster et al 13011252 - (D) BROWNE 102 MIDDLETON & REUTLINGER TAWFIK, SAMEH

3748 Ex Parte Newman 12870202 - (D) HOFFMANN 102/103 SMITH, GAMBRELL & RUSSELL HARRIS, WESLEY G

AFFIRMED-IN-PART
Tech Center 1700 Chemical & Materials Engineering
1787 Ex Parte SIMPSON et al 12273823 - (D) ROSS 112(1)/103 double patenting Fox Rothschild LLP I UTB HUANG, CHENG YUAN

"[T]he purpose of the written description requirement is to 'ensure that the scope of the right to exclude, as set forth in the claims, does not overreach the scope of the inventor's contribution to the field of art as described in the patent specification."' Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1353-54 (Fed. Cir. 2010) (en banc) (quoting Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 920 (Fed. Cir. 2004)).

Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 94 USPQ2d 1161 (Fed. Cir. 2010)(en banc) 2161 ,   2161.01 ,   2163 ,   2163.03 ,   2173.05(g) ,   2181

University of Rochester v. G.D. Searle & Co., 358 F.3d 916, 69 USPQ2d 1886 (Fed. Cir. 2004) 2163

Tech Center 2400 Networking, Multiplexing, Cable, and Security
2446 Ex Parte Barton et al 13448741 - (D) MOORE 103 103 Hewlett Packard Enterprise LIN, JSING FORNG

2479 Ex Parte Alcorn et al 13056644 - (D) NAPPI 102/103 102 HP Inc, KADING, JOSHUA A

Tech Center 3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
3682 Ex Parte Chen et al 13175743 - (D) CRAWFORD 102/103 103 Mauriel Kapouytian Woods LLP BOVEJA, NAMRATA

3733 Ex Parte Kostuik et al 14207740 - (D) CURCURI 102/103 102/103 41.50 102/103 CARTER, DELUCA, FARRELL & SCHMIDT, LLP HAMMOND, ELLEN CHRISTINA

3752 Ex Parte Belongia 12837948 - (D) CALVE 102/112(2) 112(2) 41.50 112(2) S,C JOHNSON & SON, INC KIM, CHRISTOPHER S

AFFIRMED
Tech Center 1600 Biotechnology and Organic Chemistry
1616 Ex Parte Figuly 13546594 - (D) SAWERT 112(1) 103 41.50 103 E I DUPONT DENEMOURS AND COMPANY KASSA, JESSICA M

1643 Ex Parte Gevas et al 13012433 - (D) LaVIER 103/double patenting Jenkins, Wilson, Taylor & Hunt, P.A. SANG, HONG

1657 Ex Parte Kleiber et al 13269195 - (D) SMITH 103/double patenting Roche Molecular Systems, Inc, HUMPHREY, LOUISE WANG ZHIYING

Tech Center 1700 Chemical & Materials Engineering
1747 Ex Parte Tanno et al 13585510 - (D) HASTINGS 103 GREER, BURNS & CRAIN, LTD ROGERS, MARTIN K

1747 Ex Parte Tanno et al 12447648 - (D) HASTINGS 103 GREER, BURNS & CRAIN, LTD ROGERS, MARTIN K

1756 Ex Parte Buckley et al 12935663 - (D) SQUIRE 103 ALBEMARLE CORPORATION WANGA, TIMON

1771 Ex Parte Mayeur et al 12373158 - (D) GAUDETTE 112(1) 103 SUGHRUE MION, PLLC BOYER, RANDY

1783 Ex Parte Kienzle et al 11786277 - (D) PER CURIAM 103 LERNER GREENBERG STEMER LLP MILLER, DANIEL H

Tech Center 2100 Computer Architecture and Software
2128 Ex Parte Venkatesh et al 13241941 - (D) CURCURI 103 HONEYWELL/HUSCH KHAN, IFTEKHAR A

2142 Ex Parte Wine 13462015 - (D) BAIN 102/103 KYOCERA INTERNATIONAL INC NICHOLS, JENNIFER ELIZABETH-JO

2179 Ex Parte Maxwell 13109961 - (D) JEFFERY 103 FISH & RICHARDSON P,C (APPLE) DUCKWORTH, JIANMEI F

2193 Ex Parte Ghosh et al 12838061 - (D) SMITH 103/double patenting BAKER BOTTS L.L.P. LOUIE, JUE WANG

Tech Center 2400 Networking, Multiplexing, Cable, and Security
2426 Ex Parte Sugahara 12188780 - (D) DANG 103 HAYNES AND BOONE, LLP NGUYEN, AN V

2436 Ex Parte Haselsteiner 13120849 - (D) SZPONDOWSKI 102/103 NXP B.V. LE, KHOI V

2444 Ex Parte Clark et al 11993794 - (D) YAP 103 Gowling WLG (Canada) LLP BENGZON, GREG C

2456 Ex Parte Gisby 12817349 - (D) BEAMER 103 Fleit Gibbons Gutman Bongini & Bianco P,L, NGUYEN, VAN KIM T

2483 Ex Parte Laksono et al 13076536 - (D) FISHMAN 103 Garlick & Markison (VIXS) REN, ZHUBING

Tech Center 2600 Communications
2683 Ex Parte Keinrath et al 13206409 - (D) ENGLE 103 HONEYWELL/IPL LAU, KEVIN

Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2811 Ex Parte Takashima 12685069 - (D) GARRIS 112(2) 102 PATTERSON Intellectual Property Law, P.C. LI, MEIYA

2829 Ex Parte Ko et al 12232019 - (D) HAAPALA 103 JIANQ CHYUN INTELLECTUAL PROPERTY OFFICE GUPTA, RAJ R

2881 Ex Parte Ikegami et al 13254136 - (D) PER CURIAM 102/103 MORGAN, LEWIS & BOCKIUS LLP (BO) CHUNG, KEVIN T

Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3763 Ex Parte McIntyre et al 12975200 - (D) PER CURIAM 112(1)/103 112(2) KACVINSKY DAISAK BLUNI PLLC VU, QUYNH-NHU HOANG

gordon, ariad, abbvie, rochester

custom search

REVERSED
Tech Center 2100 Computer Architecture and Software
2198 Ex Parte LU et al 12103730 - (D) ZADO 102/103 Russell Ng PLLC (IBM AUS) KABIR, MOHAMMAD H

Tech Center 2400 Networking, Multiplexing, Cable, and Security
2431 Ex Parte Hinton 11010228 - (D) KOHUT 102 IBM CORP. (DHJ) c/o DAVID H. JUDSON AVERY, JEREMIAH L

Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2842 Ex Parte Houston et al 13116973 - (D) HASTINGS 112(1)/102/103 TEXAS INSTRUMENTS INCORPORATED CHENG, DIANA

Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3741 Ex Parte Cloft 11823496 - (D) KINDER 103 Kinney & Lange, P.A. KIM, CRAIG SANG

Examining the entirety of each of the prior art references to determine whether it would have been obvious to combine Olsen’s electrically driven oil system into Champion, we conclude it would not because doing so would render Champion unsatisfactory for its intended purpose. See In re Gordon, 733 F.2d 900, 902 (Fed. Cir. 1984).

Gordon, In re, 733 F.2d 900, 221 USPQ 1125 (Fed. Cir. 1984) 2143.01 , 2144.08

AFFIRMED-IN-PART
Tech Center 2400 Networking, Multiplexing, Cable, and Security
2432 Ex Parte Moskowitz 11895388 - (D) DEJMEK 103 103 NEIFELD IP LAW, PC OKEKE, IZUNNA

2491 Ex Parte Viamonte Sole 12144201 - (D) HOMERE 102/103 102/103 RATNERPRESTIA DESROSIERS, EVANS

Tech Center 2600 Communications
2648 Ex Parte Chen et al 12170319 - (D) LENTIVECH 102 102 TEXAS INSTRUMENTS INCORPORATED BILODEAU, DAVID

Tech Center 3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
3672 Ex Parte Freeman 13168621 - (D) PLENZLER 103 102 SCHLUMBERGER-DOLL RESEARCH ANDREWS, DAVID L

AFFIRMED
Tech Center 1600 Biotechnology and Organic Chemistry
1675 Ex Parte Subkowski et al 11922650 - (D) PER CURIUM 112(1)/112(2)/102 112(1) Drinker Biddle & Reath LLP (WM) HA, JULIE

A “generic claim may define the boundaries of a vast genus of chemical compounds, and yet the question may still remain whether the specification, including original claim language, demonstrates that the applicant has invented species sufficient to support a claim to a genus.” Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1349 (Fed. Cir. 2010).

When a patent claims a genus using functional language to define a desired result, “the specification must demonstrate that the applicant has made a generic invention that achieves the claimed result and do so by showing that the applicant has invented species sufficient to support a claim to the functionally-defined genus.” AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 1285, 1299 (Fed. Cir. 2014) (quoting Ariad, 598 F.3d at 1349).

Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 94 USPQ2d 1161 (Fed. Cir. 2010)(en banc) 2161 , 2181

AbbVie Duetschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 1285, 111 USPQ2d 1780 (Fed. Cir. 2014)  2163 ,   2163.01 ,   2163.05

The Federal Circuit confronted facts similar to those here in University of Rochester v. G.D. Searle & Co., Inc., 358 F.3d 916 (Fed. Cir. 2004). In that case, the patent claimed a method of selectively inhibiting the enzyme PGHS-2 (also known as COX-2) by “administering a non-steroidal compound that selectively inhibits activity of the PGHS-2 gene product in a human.” Id. at 918. The patent “described in detail how to make cells that express either COX-1 or COX-2, but not both …, as well as ‘assays for screening compounds, including peptides, polynucleotides, and small organic molecules to identify those that inhibit the expression or activity of the PGHS-2 gene product.[’]” Id. at 927.

The court held that the disclosure of screening assays and general classes of compounds was not adequate to describe compounds having the desired activity: without disclosure of which peptides, polynucleotides, or small organic molecules have the desired characteristic, the claims failed to meet the description requirement of § 112. See id. (“As pointed out by the district court, the ‘850 patent does not disclose just ‘which “peptides, polynucleotides, and small organic molecules” have the desired characteristic of selectively inhibiting PGHS-2.’ … Without such disclosure, the claimed methods cannot be said to have been described.”).

University of Rochester v. G.D. Searle & Co., 358 F.3d 916, 69 USPQ2d 1886 (Fed. Cir. 2004) 2163

Tech Center 2100 Computer Architecture and Software
2157 Ex Parte CHAUDHRY 12430761 - (D) McKEOWN 103 THE DIRECTV GROUP, INC. PARK, GRACE A

2167 Ex Parte Wong et al 10888772 - (D) JEFFERY 103 Baker Botts LLP KHAKHAR, NIRAV K

Tech Center 2400 Networking, Multiplexing, Cable, and Security
2485 Ex Parte Baylon 11562517 - (D) DANG 103 ARRIS Group, Inc. TORRENTE, RICHARD T

REHEARING

DENIED
Tech Center 2400 Networking, Multiplexing, Cable, and Security
2444 Ex Parte Haynes et al 12140570 - (D) SHAW 103 CRGO LAW STEVEN M. GREENBERG PAPPAS, PETER